FLUIDDA is an innovative company that aims to improve patient care and development of medication in the respiratory domain based on medical imaging and computer simulations. Cooperation with universities and medical research centers worldwide resulted in numerous clinical trials in over 1000 patients. Since we are a fast-growing top technology company, we are looking for an FRI Analyst to join our team in Lisbon, Portugal. Job Overview The FRI analyst’s main task is to implement and perform medical imaging analyses, through FLUIDDA’s proprietary Functional Respiratory Imaging (FRI) technology ..read more

COPD is heterogeneous in its clinical manifestations and disease progression. Patients often have disease courses that are difficult to predict with readily available data, such as lung function testing. The ability to better classify COPD into well-defined groups will allow researchers and clinicians to tailor novel therapies and improve patient-centered outcomes. Different modalities of assessing these COPD phenotypes are actively being studied, and an area of great promise includes the use of quantitative computed tomography (QCT) techniques focused on key features such as airway anatomy, l ..read more

FLUIDDA introduces RespiNet, a model for automated segmentation of lung structures.  At the ECR 2023 conference in Vienna, FLUIDDA presents their deep learning model for the segmentation of the lobes and airway tree in volumetric, thin-slice CT scans called RespiNet. RespiNet is developed by FLUIDDA and is a deep learning model for the segmentation of the lobes and airway tree in volumetric, thin-slice CT scans. The presentation will be March 1sth, session RPS 405, 13.00-13.45 CET. The post RespiNet – A model for automated segmentation of lung structures. appeared first o ..read more

Pulmonary Hypertension (PH) patients need more treatment options, and it seems the Merck’s MK5475 inhaled drug is quite promising! FLUIDDA’s FRI technology showed substantial and homogeneous vasodilation throughout the lung associated with an improvement in hemodynamics as measured by right heart catheterization. https://www.resmedjournal.com/article/S0954-6111(22)00330-4/fulltext The Holy Grail in the treatment of Pulmonary Arterial Hypertension  is to demonstrate remodeling of the abnormal blood vessel wall. FLUIDDA has taken a major step towards reaching this goal by developing a propr ..read more

In a recent publication in BMC Pulmonary Medicine (2022) 22:477, Ides et all. Investigated how body positioning can affect the regional distribution of lung ventilation and blood flow in healthy subjects. Correct body positioning is a potential tool to improve regional ventilation, thereby possibly enhancing the effect of respiratory physiotherapy interventions. In a proof-of-concept study, functional respiratory imaging (FRI) was used to objectively assess effects of body position on regional airflow distribution in the lungs. It was concluded that changing body ..read more

MedImprove, a multidisciplinary medical center for respiratory revalidation which makes use of Fluidda’s propietary FRI technology, was featured in a recent publication of the Belgian daily newspaper ” De Standaard”. A new innovative imaging technique makes it possible to treat and monitor people with lung disorders in a very targeted and efficient manner. (Source: “De Standaard”, Belgian Daily Newspaper, December 10, 2022) Holistic and personalized rehabilitation Prof. De Backer: “Medimprove is a multidisciplinary medical centre with academically qualified physiotherapists and nurses that mai ..read more

Novel outcome measures for cystic fibrosis in a changing world Very recently Eline Lauwers, working for Fluidda in Belgium, defended a dissertation called: “Novel outcome measures for cystic fibrosis” to acquire the PhD. title. During her research she compared two novel techniques to improve the identification of regional abnormalities in the lungs of cystic fibrosis patients: Functional Respiratory Imaging (FRI) a technology developed by Fluidda and Computer Aided Lung Sound Analysis (CALSA). Cystic fibrosis is a life-threatening genetic disease, characterized by an early onset of progre ..read more

Will you be attending RSNA 2022, November 27th – December 1st in Chicago? Then you have a possibility to learn all about Broncholab®. Fluidda will be present to explain all features of this new Medical Device. Broncholab® enables accurate monitoring of the course of lung diseases, thus increasing insights in the nature of the disease and supporting physicians in diagnosis and follow-up. Broncholab’s Blood vessel measurements (BV5, BV5_10, etc.) can be used to detect changes in lung structure which may be associated with pulmonary vascular remodelling and other pathologic processes in ..read more

The exact prevalence of COPD worldwide is largely unknown, but estimates have varied from 7-19%. The Burden of Obstructive Lung Disease (BOLD) study found a global prevalence of 10.1%. According to WHO estimates, 65 million people have moderate to severe chronic obstructive pulmonary disease (COPD). More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. (WHO) From it’s start in 2005, Fluidda supports both HCP’s as companies who develop new medication for COPD to lighten the burden on COPD patients with their proprietary Fu ..read more

During the last ERS conference in Barcelona, Eline Lauwers, who recently obtained het PhD degree based on research partially conducted at Fluidda, presented a poster on her latest findings. She investigated a new approach relating lung sounds to airflow turbulence intensity using computational fluid dynamics (CFD) in cystic fibrosis patients. Cystic fibrosis is a life-threatening genetic disease, characterized by an early onset of progressive lung disease. The conclusions of her investigations can be read in the poster below. ePoster ERS 2022 Eline LauwersDownload The post ERS2022 – Digital lu ..read more